StreetInsider.com News Articles

Form 8-K Acurx Pharmaceuticals, For: Oct 16

Fri, 16 Oct 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20261016/27198282.html

Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street

Mon, 05 Oct 2026 13:25:00 -0400

NEW YORK CITY, NY / ACCESS Newswire / October 5, 2026 / Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) has signed a 12-month media series with New to The Street. The series will bring the Company's work on a new class of antibiotics to investors in the United States, Latin America, the Middle East and North Africa (MENA) and Southeast Asia.

Each month, Acurx leadership will appear in a long-form interview broadcast on Bloomberg Television as sponsored programming in all four regions. Each interview will also be distributed on New to The Street TV, one of

Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street

Mon, 05 Oct 2026 13:25:00 -0400

Acurx enrolls first patient in PATHFINDER trial for C. difficile

Tue, 29 Sep 2026 08:02:30 -0400

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced Sept. 29 that the first patient has been enrolled in its PATHFINDER Phase 2 clinical trial, evaluating ibezapolstat in patients with multiply-recurrent C. difficile infection (rCDI).

The fully funded, multicenter, open-label, single-arm pilot trial will enroll approximately 20 patients who have experienced at least three episodes of CDI within the past 12 months. Participants will receive ibezapolstat for 14 days and be assessed for clinical cure, sustained clinical cure, recurrence rate through week 24, and extended clinical cure through week 24.

Acurx stated that data from PATHFINDER, if successful, would support a U.S. New Drug Application

Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection

Tue, 29 Sep 2026 08:01:00 -0400

PATHFINDER is a ground-breaking Phase 2 clinical trial with ibezapolstat (IBZ) in patients with multiply-recurrent CDI (C. difficile Infection) (rCDI) that, together with results from the planned ASPIRE Phase 3 trial in the broader patient population for the treatment of acute CDI, has potential to shift the paradigm of treatment and prevention of rCDI from two agents to one

Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection

Tue, 29 Sep 2026 08:01:00 -0400

PATHFINDER is a ground-breaking Phase 2 clinical trial with ibezapolstat (IBZ) in patients with multiply-recurrent CDI (C. difficile Infection) (rCDI) that, together with results from the planned ASPIRE Phase 3 trial in the broader patient population for the treatment of acute CDI, has potential to shift the paradigm of treatment and prevention of rCDI from two agents to one

New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global

Sat, 19 Sep 2026 11:45:00 -0400

NEW YORK CITY, NY / ACCESS Newswire / September 19, 2026 / New to The Street, one of the world's longest-running sponsored and syndicated business television programs, announces tonight's broadcast featuring executives from BioVie Inc. (Nasdaq:BIVI), Acurx Pharmaceuticals, Inc. (Nasdaq:ACXP), Lantern Pharma Inc. (Nasdaq:LTRN) and SafeSpace Global.

The program airs tonight at 6:30 PM Eastern Time across Bloomberg Television's U.S., Latin America and Middle East and North Africa markets, giving viewers access to executive interviews covering biotechnology, pharmaceutical innovation, artificial intelligence and next-generation security technology.

BioVie Inc. (Nasdaq:BIVI)

BioVie President and CEO Cuong Do discusses

New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global

Sat, 19 Sep 2026 11:45:00 -0400

BioVie Inc. (Nasdaq:BIVI)

BioVie President and CEO Cuong Do discusses

New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global

Sat, 19 Sep 2026 11:45:00 -0400

BioVie Inc. (Nasdaq:BIVI)

BioVie President and CEO Cuong Do discusses

New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global

Sat, 19 Sep 2026 11:45:00 -0400

BioVie Inc. (Nasdaq:BIVI)

BioVie President and CEO Cuong Do discusses

New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global

Sat, 19 Sep 2026 11:45:00 -0400

BioVie Inc. (Nasdaq:BIVI)

BioVie President and CEO Cuong Do discusses

New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global

Sat, 19 Sep 2026 11:45:00 -0400

BioVie Inc. (Nasdaq:BIVI)

BioVie President and CEO Cuong Do discusses

Form EFFECT Acurx Pharmaceuticals,

Fri, 18 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260918/27077821.html

Form 424B3 Acurx Pharmaceuticals,

Thu, 17 Sep 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260917/27076569.html

Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomi

Mon, 14 Sep 2026 08:01:00 -0400

The microbiome of patients experiencing recurrent CDI is frequently dominated by overgrowths of Enterococcus species
This study evaluated the in vitro bactericidal and molecular efficacy of ibezapolstat (IBZ), vancomycin (VAN), and fidaxomicin (FDX) against C. difficile and Enterococcus in standalone and complex co-culture environments

Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomi

Mon, 14 Sep 2026 08:01:00 -0400

The microbiome of patients experiencing recurrent CDI is frequently dominated by overgrowths of Enterococcus species
This study evaluated the in vitro bactericidal and molecular efficacy of ibezapolstat (IBZ), vancomycin (VAN), and fidaxomicin (FDX) against C. difficile and Enterococcus in standalone and complex co-culture environments

Acurx gets FDA conditional brand name acceptance for CDI drug

Mon, 17 Aug 2026 08:02:36 -0400

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced that the FDA has conditionally accepted the proposed brand name CIFBEZY for ibezapolstat, its antibiotic candidate for Clostridioides difficile infection (CDI). The U.S. Patent and Trademark Office (USPTO) has also allowed the trademark application for the name.

According to a company statement, the name CIFBEZY was developed through a screening process involving branding experts, prescribers, pharmacists, and linguists, as evaluated by the FDA's Division of Medication Error Prevention and Analysis. A request for final FDA review and approval of the brand name is required at the time of a New Drug Application (NDA) submission.

The USPTO's

Acurx gets FDA conditional brand name acceptance for CDI drug

Mon, 17 Aug 2026 08:02:36 -0400

The USPTO's

Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat